A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser cohort study

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 7, 2011, Pages 1398-1409

  Schiffman, Mark ^a   Glass, Andrew G ^b   Wentzensen, Nicolas ^a   Rush, Brenda B ^b   Castle, Philip E ^a   Scott, David R ^b   Buckland, Julie ^c   Sherman, Mark E ^a   Rydzak, Greg ^c   Kirk, Peter ^a   Lorincz, Attila T ^d   Wacholder, Sholom ^a   Burk, Robert D ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c INFORMATION MANAGEMENT SERVICES INC   (United States)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENICITY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL LAVAGE;

EID: 79960084939     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0206     Document Type: Article

References (38)

1. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
2. Reeves WC, Brinton LA, García M, Brenes MM, Herrero R, Gaitán E, et al. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med 1989;320:1437-41. (Pubitemid 19143707)
3. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52. (Pubitemid 36124295)
4. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
5. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-53. (Pubitemid 39273789)
6. Cuzick J, Szarewski A, Mesher D, Cadman L, Austin J, Perryman K, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer 2008;122:2294-300. (Pubitemid 351542334)
7. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65. (Pubitemid 34293391)
8. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009;10:321-2.
9. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8:1663-79.
10. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. (Pubitemid 47371147)
11. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62. (Pubitemid 35446606)
12. ACOG Practice Bulletin no. 109: Cervical cytology screening. Obstet Gynecol 2009;114:1409-20.
13. IARC handbooks of cancer prevention. Vol 10. Cervix cancer screening. Lyon: IARC Press; 2005.
14. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9. (Pubitemid 41417924)
15. Burk RD, Kadish AS, Calderin S, Romney SL. Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear. Am J Obstet Gynecol 1986;154:982-9. (Pubitemid 16085711)
16. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, et al. The accuracy of colposcopic biopsy: Analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 2010.
17. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417-23.
18. Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol 2003;41:4022-30. (Pubitemid 37099659)
19. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93. (Pubitemid 30038388)
20. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M, et al. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008;46:2595-604.
21. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64. (Pubitemid 23177581)
22. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91:954-60. (Pubitemid 29272522)
23. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
24. Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010;102:1478-88.
25. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-7.
26. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
27. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72. (Pubitemid 350137476)
28. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V, et al. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med 2010;170:977-85.
29. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
30. Kjaer S, Høgdall E, Frederiksen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66:10630-6. (Pubitemid 44799787)
31. Hoyer H, Scheungraber C, Kuehne-Heid R, Teller K, Greinke C, Leistritz S, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer 2005;116:136-43. (Pubitemid 40827767)
32. Rodríguez AC, Schiffman M, Herrero R, Hildesheim A, Bratti C, Sherman ME, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010;102:315-24.
33. Naucler P, Ryd W, T€ornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97. (Pubitemid 47598401)
34. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer 2010;102:1405-10.
35. Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006;66:10112-9. (Pubitemid 44672065)
36. Castle PE, Rodriguez AC, Porras C, Herrero R, Schiffman M, Gonzalez P, et al. A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007;34:849-55. (Pubitemid 350301046)
37. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009;125:2151-8.
38. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE, et al. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009;101:475-87.